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Abstract 
Variation in telomere length is heritable and is currently considered a promising 
biomarker of susceptibility for neuropsychiatric disorders, particularly because of its 
association with memory function and hippocampal morphology. Here, we 
investigate telomere length in connection to familial risk and disease expression in 
bipolar disorder (BD). We used quantitative polymerase chain reactions and a 
telomere-sequence to single-copy-gene-sequence ratio method to determine 
telomere length in genomic DNA extracted from buccal smears from 63 patients with 
BD, 74 first-degree relatives (49 relatives had no lifetime psychopathology and 25 
had a non-BD mood disorder) and 80 unrelated healthy individuals. Participants also 
underwent magnetic resonance imaging to determine hippocampal volumes and 
cognitive assessment to evaluate episodic memory using the verbal paired 
associates test. Telomere length was shorter in psychiatrically-well relatives 
(p=0.007) compared to unrelated healthy participants. Telomere length was also 
shorter in relatives (regardless of psychiatric status; p<0.01) and patients with BD 
not on lithium (p=0.02) compared to lithium-treated patients with BD.  In the entire 
sample, telomere length was positively associated with left and right hippocampal 
volume and with delayed recall. This study provides evidence that shortened 
telomere length is associated with familial risk for BD. Lithium may have 
neuroprotective properties that require further investigation using prospective 
designs.    
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Introduction 
 
Telomeres are DNA repeat structures (TTAGGG) at the end of each chromosome 
that undergo shortening during mitosis (Allsop et al, 1992; Stewart et al, 2012).  
Telomere shortening has been associated with exposure to cellular stressors 
(Saretzki and Von Zglinicki, 2002), lifestyle factors (Valdes et al, 2005) and social 
adversity (Epel et al, 2004; Giaganaros et al, 2007; Shalev et al, 2013) while 
telomerase, an enzyme that adds DNA sequence repeats (TTAGGG) onto the 3’ 
telomeric end, may reverse or mitigate this process (Allsop et al, 1992; Stewart et al, 
2012). Cell senescence or cell death is triggered when a critically short telomere 
length is reached (Stewart et al, 2012). Telomere length is therefore considered a 
promising biomarker of biological aging and susceptibility to disease (Calado 2009; 
Heidinger et al, 2011).  
 
The relationship between telomere length and psychiatric disorders is a topic of 
much interest but also uncertainty (Eitan et al, 2014). Previous studies have reported 
shortened peripheral telomere length in major depressive disorder (MDD) 
(Verhoeven et al, 2016; Hartmann et al, 2010; Lung et al, 2007), schizophrenia 
(SCZ) (Yu et al, 2008) as well as different forms of dementia (Mouiha et al, 2011; 
Rabinovici et al, 2007). In Bipolar Disorder (BD), individual studies have reported 
both reduced (Barbé-Tuana et al, 2016; Lima et al, 2013) and increased telomere 
length in patients compared to unrelated healthy individuals (Martinsson et al, 2013; 
Simon et al, 2006). The heterogeneity of the primary studies is reflected in recent 
meta-analyses which either failed to find an effect of diagnosis (Colpo et al, 2015) or 
reported a small effect (Darrow et al, 2016). In post-mortem brain tissue, decreased 
telomere length has been found in the hippocampus of patients with SCZ, BD and 
MDD suggesting that telomere shortening may be more relevant or pronounced in 
this brain region (Mamdani et al, 2015).  
 
Telomere length is associated with brain morphology, particularly the hippocampus 
(King et al, 2014; Nilsonne et al, 2015), a brain region that appears vulnerable to 
multiple disease mechanisms (Hibar et al, 2016; Rabinovici et al, 2007;Schmaal et 
al, 2016; van Erp et al, 2016; Mouiha et al, 2011) which is also capable of 
neurogenesis (Barnes et al, 2009; Spalding et al, 2013). Telomere length is also 
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associated with memory function (Valdes et al, 2010) including episodic memory that 
is closely linked to hippocampal function (Dickerson and Eichenbaum, 2010; Kühn 
and Gallinat, 2014; van Petten, 2004). Telomere shortening may therefore represent 
a common biological mechanism linking hippocampal abnormalities and deficits in 
episodic memory, both of which have been consistently reported in psychiatric 
disorders (Bora et al, 2013; Bourne et al, 2013; Lim et al, 2013; Szöke et al, 2008). 
 
In the case of BD, psychotropic treatment may influence telomere length. There is 
convincing evidence that patients on long-term lithium treatment have longer 
telomeres (Martinsson et al, 2013; Squassina et al, 2016) while the case regarding 
antidepressants remains equivocal (Verhoeven et al, 2017; Bersani et al. 2014; 
Soeiro-de-Souza et al, 2011). The relationship between telomere length and BD is 
therefore complex, implicating both disease- and treatment-related mechanisms. 
One way to disentangle these effects is to examine first-degree relatives of patients, 
as telomere length shows high heritability (Slagboom et al, 1994). Accordingly, we 
examined telomere length in remitted patients with BD, first degree relatives of 
patients, and unrelated healthy comparison individuals. We further investigated the 
effect of psychotropic treatment on telomere length and the association between 
telomere length with hippocampal volume, and episodic memory.     
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Patients and Methods 
Buccal DNA was available from 217 individuals of white British ancestry who had 
participated in the Vulnerability to Bipolar Disorders Study (VIBES), described 
previously (Delvecchio et al, 2015; Dima et al, 2013; Dima et al, 2016; Forcada et al, 
2011; Frangou, 2009; Frangou, 2011, Jogia et al, 2012; Jogia et al, 2011; Kempton 
et al, 2009; Lelli-Chiesa et al, 2011; Perrier et al, 2011; Pompei et al, 2011a; Pompei 
et al, 2011b; Ruberto et al, 2011; Takahashi et al, 2011). The VIBES sample 
includes (a) patients that fulfil criteria for BD-I based on the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition, revised (DSM-IV) (American Psychiatric 
Association, 1994) (b) first-degree relatives and, (c) unrelated healthy individuals 
without a personal or family history of psychiatric disorders. Patients and relatives 
were screened to exclude pedigrees with schizophrenia or schizophrenia spectrum 
disorders. Exclusion criteria for all participants were current and hereditary 
neurological disorders, DSM-IV lifetime drug or alcohol dependence or drug or 
alcohol abuse in the preceding six months and contraindications to magnetic 
resonance imaging (MRI). Trained psychiatrists and clinical psychologists 
respectively conducted clinical interviews and cognitive assessments. Diagnostic 
assessments were based on the Structured Clinical Interview for DSM-IV disorders 
(First et al, 2002a,b) and psychopathology was rated using the Hamilton Depression 
Rating Scale (HDRS; Hamilton, 1960) and the Young Mania Rating Scale (YMRS; 
Young et al, 1978). The study received institutional ethical approval. All individuals 
provided written informed consent prior to participation. 
 
The study sample comprised 63 patients with BD, 74 first-degree relatives 
(siblings=35; offspring=39) and 80 unrelated healthy volunteers (Table 1 and 
supplemental Table S1 and S2); 27 patients with BD and 8 relatives were unrelated 
to any other participant in the database. Of the first-degree relatives, 21 had a 
lifetime diagnosis of Major Depressive Disorder and 4 of Anxiety Disorders 
(supplemental Table S1). All participants with psychiatric diagnoses were in 
remission at the time of study enrolment defined as a HDRS and YMRS score below 
7 (Table 1), in accordance with the criteria set by the task force of International 
Society for Bipolar Disorders (Tohen et al, 2006). All but 4 patients with BD were 
medicated as detailed in Table 1. Also, 15 of the 25 relatives with non-BD psychiatric 
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diagnoses were prescribed antidepressants as monotherapy at the time of study 
participation (Table 1). Relatives with non-BD diagnoses who were not on treatment 
had been either medication naïve (n=7) or had not received any psychotropic 
treatment for more than a year.  
 
Cognitive Assessment 
In all participants, an estimate of general intellectual ability was obtained using the 
Wechsler Adult Intelligence Scale-Revised (Wechsler, 1981) and episodic memory 
was assessed using verbal paired associates (VPA) test from the Wechsler Memory 
Scale–Third Edition (Wechsler, 1997). This is the most widely used instrument for 
the assessment of hippocampus-linked memory (van Petten et al, 2004). Scaled 
scores for VPA-immediate and VPA-delayed recall were used in the analyses. 
 
Determination of Telomere Length   
Buccal DNA was extracted using a standardised procedure (Freeman et al, 1999). 
DNA samples had good purity ratios (260/280 ratios of between 1.7–1.9), as 
measured using the Nanodrop, ND1000 (Thermoscientific, Wilmington, DE). 
Telomere length was quantified using quantitative real-time polymerase chain 
reaction (qPCR) assays as previously described (Cawthon, 2009; Vincent et al., 
2017) performed on the ABI Prism 7900HT Sequence Detection System, with the 
output generated using SDS Software version 2 (details in supplemental material). 
Telomere lengths are reported as relative ratios of the copy number of telomere DNA 
(TTAGGG) to a single-copy gene (albumin). The telomere length was normally 
distributed in the entire sample (Kolmogorov-Smirnov p=0.09). Eleven specimens 
were excluded because they either failed quality control (n=4) or were identified as 
outliers (n=7) (telomere length > than 2 standard deviations). The telomere length 
was negatively associated with age in the entire sample (beta=−0.18; t=-2.72; 
p=0.007) but not with sex (beta=0.07; t=1.09; p=0.29). Further analyses showed that 
the regression slopes were not statistically different by sex or diagnostic group as 
detailed in supplemental material (Figure S2 and Tables S3-S5). Following linear 
regression of age and sex, the standardized residuals of the telomere length, 
referred to as age-and-sex-adjusted telomere length, were used in most downstream 
analyses.  
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MR Imaging  
High-resolution T1-weighted whole brain MR images were obtained on a GE Signa 
HD 1.5T MR imaging system using an inversion recovery prepared, spoiled gradient-
echo sequence. Whole brain coverage was obtained in axial orientation with slice 
thickness of 1.5mm, repetition time of 18 milliseconds, echo time of 5.1 milliseconds, 
flip angle of 20°, field of view=240x180mm, and voxel 
dimensions=0.9375x0.9375x1.5mm. Following pre-processing, we used FreeSurfer, 
version 5.3.0 (http://surfer.nmr.mgh.harvard.edu/), a widely used and validated 
software, to segment and respectively quantify total intracranial and left and right 
hippocampal volume. Segmented regions were visually inspected and statistically 
evaluated for outliers.   
 
Statistical analysis 
Group differences were examined using analysis of variance (followed by post-hoc 
tests) and independent t-tests, as appropriate. Family membership was modelled as 
a repeated measure. Bivariate associations were assessed using Spearman 
correlation coefficient and regression analyses were used to model the contribution 
of multiple predictors. We first examined the effect of potential confounders, namely 
medication in patients and the relatives and the effect of psychiatric status (with 
regard to non-BD diagnoses) in the relatives to determine the number of groups and 
variables to be considered. Analyses were performed in SPSS (Version 22, IBM, 
New York, USA).    
 
Results 
Examination of Confounders 
Telomere length and Medication in Patients with BD  
Details on medication are shown in Table 1. In patients with BD, the mean duration 
of treatment with lithium was 3.8 years (range: 6 months to 40 years) and the mean 
dose was 904mg (range 600-1200mg). Lithium dose and treatment duration did not 
correlate with telomere length (p>0.13). Lithium treatment status was not associated 
with differences in age of onset, or HDRS and YMRS scores (p>0.94). Only four 
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patients with BD who were not on current treatment with lithium had been prescribed 
this medication at some point in the past.  
We then examined the effect of medication (on lithium vs. not on lithium, on 
antidepressants vs. not on antidepressants; typical antipsychotic, atypical 
antipsychotic, none; carbamazepine, lamotrigine, sodium valproate, none) on age-
and-sex-adjusted telomere length in patients with BD. We first tested the effect of 
each individual class and then considered all classes together. Treatment with 
lithium was associated with longer telomeres (t60=-2.24, p=0.03). We found no effect 
of antidepressants (t60=1.13, p=0.16), antipsychotics (F2,60=0.57, p=0.57) or 
anticonvulsants (F3,60=1.69, p=0.15). When all medications and their interactions 
were considered, there was still an overall effect of lithium (F1=4.01, p=0.04) but the 
main effects and interactions with the other medication classes were not significant 
(p>0.22).  
 
Telomere length and Medication in Relatives of patients with BD 
Relatives had only been exposed to antidepressants. A multiple regression analysis 
did not support an association between telomere length an antidepressant treatment 
(beta=-0.02, t=-0.33; p=0.73) in relatives; in the same model we found a significant 
association with age (beta=-0.19, t=-2.37; p=0.01) but not sex (beta=0.10, t=1.32; 
p=0.18). Moreover, age-and-sex-adjusted telomere length did not differ between 
relatives based on their antidepressant exposure (F1,63=1.79, p=0.18). Further 
analyses on the association between of antidepressants and telomere length can be 
found in supplemental material. 
 
Telomere length and Psychiatric Status in Relatives of patients with BD 
Age-and-sex-adjusted telomere length differed between relatives with psychiatric 
diagnoses, psychiatrically-well relatives and healthy volunteers (F2,154=4.24, p=0.01). 
Post-hoc Bonferroni corrected pairwise tests showed that healthy relatives had 
significantly shorter telomere length than healthy volunteers (p=0.02) while no other 
pairwise comparison was significant (p>0.20). 
 
Primary Analyses 
Having established which confounders were relevant, we proceeded to carry out a 
series of hypothesis-driven analyses. 
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Telomere Length in Patients with Bipolar Disorder and First-Degree Relatives 
Based on the results above we considered 5 groups in our final analysis, namely 
unrelated healthy participants, psychiatrically-well relatives, relatives with psychiatric 
diagnoses, patients with BD on lithium and patients with BD not on lithium. We found 
an overall effect of group on age-and-sex adjusted telomere length (F4,217=3.79, 
p=0.005).  Post-hoc Bonferroni corrected pairwise tests showed that compared to 
unrelated healthy participants, telomere length was shorter in psychiatrically-well 
relatives (p=0.007; Figure 1) and relatives with psychiatric diagnoses, although at 
nominal statistical significance (p=0.07). Lithium-treated patients with BD had longer 
telomere length compared to psychiatrically-well relatives (p=0.001), relatives with 
psychiatric diagnoses (p=0.01) and patients with BD not on lithium (p=0.02); all other 
pairwise comparisons were not significant.  
 
Telomere length and Hippocampal volume 
The mean and standard deviation of the hippocampal volumes are shown in Table 1 
and Table S10. There was no effect of group (i.e., healthy volunteers, psychiatrically-
well relatives, relatives with psychiatric diagnoses, patients with BD on lithium, 
patients with BD not on lithium) on intracranial volume (ICV) (F2,162=0.98, p=0.37) 
and no effect of age (F1,162=0.59, p=0.44) but a significant effect of sex (F1,162=4.48, 
p=0.03). There was no significant effect of group on hippocampal volumes (left 
F4,173=0.81, p=0.51; right F4,173=1.59, p=0.17); the effects of age and sex were 
significant (p<0.001) but not the group-by-sex-by-age interaction (p>0.50). We found 
no significant correlation between hippocampal volumes and lithium dose or duration 
of lithium treatment (p>0.14) in patients with BD; we found no significant correlation 
between hippocampal volumes and antidepressant treatment in patients with BD or 
relatives (p>0.14).  
 
We found no difference in the slopes between telomere length and left and right 
hippocampal volumes with respect to group (Figure S3 and S4, Table S6 and S7) or 
sex (Figures S5 and S6 and Tables S8 and S9).  Telomere length explained a 
substantial amount of the variance of the left (adjusted R2=0.21, beta=0.46, p<0.001, 
95% confidence intervals: 0.32, 0.58) and right (adjusted R2=0.22, beta=0.47, 
p<0.001, 95% confidence intervals: 0.31, 0.56) hippocampal volume (Figure 2). 
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Telomere length and Episodic Memory 
The mean and standard deviation of the memory variables are shown in Table 1. 
There was no significant main effect of group (healthy volunteers, psychiatrically-well 
relatives, relatives with psychiatric diagnoses, patients with BD with BD on Lithium, 
patients with BD not on lithium) on IQ (F4,184=2.36, p=0.20). There was a significant 
effect of group on VPA-immediate recall (F4,184=2.59, p=0.04). Non-lithium treated 
patients with BD (p=0.008) and relatives with psychiatric diagnoses performed worse 
than healthy volunteers (p=0.05). Similarly, there was a significant main effect of 
group on VPA-delayed recall (F4,184=8.51, p<0.001). Compared to unrelated healthy 
volunteers, delayed recall was reduced in psychiatrically-well relatives (p<0.001), 
relatives with psychiatric diagnoses (p<0.001), and non-lithium treated patients with 
BD (p=0.05).  
 
We found no difference in the slopes between telomere length and VPA-immediate 
and VPA-delayed recall with respect to group (Figure S7 and S9, Table S11 and 
S13) or sex (Figures S8 and S10 and Tables S12 and S14).  Telomere length 
explained a non-significant amount of the variance in VPA-immediate recall 
(adjusted R2=0.004; beta=0.09; p=0.19, 95% confidence intervals: -0.26, 1.31). 
Telomere explained a small but significant amount of the variance for VPA-delayed 
recall (adjusted R2=0.02 0; beta=0.14, p=0.05; 95% confidence intervals: -0.003, 
1.25) (Figure 2).    
 
Telomere length and clinical features  
We examined correlations between age-and-sex-adjusted telomere length and 
severity of manic and depressive psychopathology, number of episodes (total, 
manic, depressive, mixed) and age of onset. None was significant (ρ<0.15, p>0.10). 
  
Powell et al.  Telomere and bipolar disorder 
 11
 
Discussion 
 
This is the first study to-date to demonstrate a link between shorter telomere length 
and familial risk for BD. Lithium treatment was associated with telomere length such 
that patients on long-term lithium treatment had longer telomeres compared to 
relatives and patients with BD who were not treated with lithium. In the entire 
sample, telomere length was also associated with larger hippocampal volume and 
better episodic memory.  
 
Our results suggest that shorter telomere length may be a common factor linking 
genetic liability to BD to multisystem disorder vulnerability. Shorter telomeres have 
been associated with multiple adverse health outcomes, primarily cardiovascular 
disease (Brouilette et al, 2003; D’Mello et al, 2015; Fitzpatrick et al, 2007; O’Donnell 
et al, 2008), type 2 diabetes (O’Donnell et al, 2008), age-related cognitive 
dysfunction (Yaffe et al, 2011) and dementia (Panossian et al, 2003; Thomas et al, 
2008). Comorbidities such as hypertension, elevated lipids, poor glycemic control 
and diabetes type 2 are more prevalent in patients with BD compared to the general 
population (Beyer et al, 2005; Czepielewski et al, 2013; Fiedorowicz et al, 2010; 
Forty et al, 2014; McIntyre et al, 2006; McIntyre et al, 2010; Smith et al, 2013). 
Although psychotropic medication may contribute to physical morbidity, 
cardiometabolic disturbances in patients with BD have been observed independent 
of medication exposure (Maina et al, 2008; Regenold et al, 2002). Medical morbidity 
in relatives of patients with BD is understudied but according to a recent study, 26% 
of first-degree relatives of patients with BD self-reported a cardiometabolic disorder 
as compared to 13% of individuals without a family history of psychiatric disorders 
(Mothi et al, 2015).  Patients with BD are also at greater risk of developing dementia 
later in life compared to patients with non-psychiatric disorders (da Silva et al, 2013; 
Kessing and Nilsson, 2003) but this association has not been examined in first-
degree relatives. 
 
Telomere length was shorter in first-degree relatives compared to unrelated healthy 
comparison individuals potentially reflecting the cumulative lifetime burdens of 
genetic and environmental exposures. Although shorter telomere length has been 
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linked to insufficient telomerase activity (Blackburn, 1991; Lu et al, 2013), large 
population-based studies suggest individuals with shorter telomeres (Epel et al, 
2008; Farzaneh-Far et al, 2010), including those individual experiencing significant 
distress (Damjanovic et al, 2007), may have upregulated telomerase, which 
maintains telomere length. Telomerase activity has not been assessed in individuals 
with familial risk for BD, but in patients longer telomere length has been associated 
with lithium-induced increase in telomerase activity (Martinsson et al, 2013; Wei et 
al, 2015; Squassina et al, 2016). Alternatively, longer telomere length in BD may be 
predictive of good lithium response and hence long-term lithium treatment. The 
cross-sectional nature of the current study does not allow us to resolve the direction 
of causality. We did not find evidence that antidepressants influence telomere length 
in patients with BD or their relatives, which is consistent with the lack of such an 
association reported in larger studies (Verhoeven et al, 2017) 
 
We confirmed previously reported associations between telomere length, 
hippocampal volume (King et al, 2014; Nilsonne et al, 2015) and episodic memory 
(Valdes et al, 2005) that support the notion that telomere length is a marker of 
hippocampal vulnerability linked to reduced cell proliferation potential (Wolkowitz et 
al, 2015). Reduction in proliferative potential is likely to affect primarily cells capable 
of division in the adult brain; these would include neural stem cells located in the 
dentate gyrus (Gage et al, 1995; Palmer et al, 1997) and other cells that support 
neuronal function (e.g, microglia, astrocytes, oligodendrocytes, and pericytes). In 
preclinical studies, telomerase induction has been shown to reverse tissue 
degeneration (Jaskelioff et al, 2011; Shingu et al, 2015) and restore proliferative 
potential of neuronal progenitor cells (Jaskelioff et al, 2011) which may account for 
the association between lithium treatment and decreased risk of developing 
dementia in patients with BD (da Silva et al, 2013; Kessing et al, 2008). 
 
There are several methodological considerations pertinent to this study. Telomere 
length was ascertained from buccal rather than brain tissue. However, previous 
studies have found that this is an acceptable surrogate since genetic influences on 
the regulation of telomere length appear tissue independent (Dlouha et al, 2014; 
Friedrich et al, 2000). We conducted a number of analyses to estimate and 
subsequently model the contribution of potential confounding (e.g., medication) and 
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moderating variables (e.g., age). No correction for multiple comparisons was applied 
to these analyses as the intention was to identify all potential sources of variance in 
this dataset and account for them in hypothesis-testing. The results of our hypothesis 
driven analyses survive Bonferroni correction.  Medication adherence was based on 
participants’ self-report. We considered these reports largely valid given that patients 
had remained on their prescribed medication for long periods and were in remission 
at study entry. As telomere length changes over time, longitudinal designs are critical 
in delineating the trajectories of change. However, general population samples have 
found no evidence of accelerated telomere shortening over follow-up periods of 5-10 
years in people with depression or anxiety disorders (Hoen et al., 2011; Verhoeven 
et al., 2016; 2017). Telomere shortening has been associated with adversity (Epel et 
al, 2004; Giaganaros et al, 2007; Shalev et al, 2013), oxidative stress and 
inflammation (Masi et al, 2012; O’Donovan et al, 2011; Saretzki and Von Zglinicki, 
2002), insulin resistance and type 2 diabetes (Demissie et al, 2006), obesity and 
smoking (Valdes et al, 2005). Additionally, telomere length may also be influenced 
by other genetic risk factors for BD. Examination of the complex interface between 
these factors, telomere length and BD in longitudinal studies will further enrich our 
understanding of the biological mechanisms involved. 
 
To our knowledge, this study provides the first evidence linking telomere length to 
familial propensity to BD. An increased understanding of telomere biology may lead 
to potential therapeutic interventions to maintain telomere length or reverse telomere 
attrition. In clinical practice, it would be advisable to target modifiable risk factors 
such as smoking, obesity, and stress and promote protective factors relating to 
healthy lifestyle and physical activity (Cherkas et al, 2008). Furthermore, targeting 
telomerase or other associated proteins may provide novel pharmacological targets 
that could address both mental and physical morbidity in those predisposed to or 
suffering from BD.   
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Table 1. Sample Characteristics  
 Patients with  
BD  
on Lithium 
 
 
N=28 
Patients with 
BD 
Not on 
Lithium 
 
N=35 
Relatives 
with psychiatric 
diagnoses 
 
 
N=25 
Psychiatrically  
Well Relatives  
 
 
 
N=49 
Unrelated  
Healthy  
Individuals 
 
 
N=80 
Age (years)a 45.53 (10.23) 42.91 (10.65) 30.40 (9.84) 36.59 (14.74) 39.71 (14.82) 
Sex, n  (% male)  13 (46.40) 17 (48.60) 9 (36.0) 23 (46.9) 36 (45) 
IQ 116.30 (14.21) 121.19 (21.48) 108.80 (14.25) 118.78 (16.87) 121.82 (19.88) 
WMS-VPA: immediate recall  11.86 (1.95) 10.45 (32.26) 9.23 (2.85) 10.97 (3.36) 11.92 (3.16) 
WMS-VPA: delayed recall 12.07 (1.24) 10.33 (2.83) 8.71 (4.44) 10.87 (2.85) 12.18 (1.85) 
Hamilton Depression Rating 
Scaleb  
3.53 (4.37) 4.31 (4.87) 1.44 (2.23) 0.23 (0.67) 0.17 (0.61) 
Young Mania Rating Scaleb 1.17 (2.55) 1.17 (2.10) 0.32 (1.14) 0.04 (0.29) 0.15 (0.45)
Age of onset of Bipolar Disorder 
(years) 
24.36 (7.33) 26.54 (9.27) n/a n/a n/a 
Any Medication, n (%)c 28 (100%) 30 (85.70) 15 (20.27) 0 n/a 
Any Antidepressant (n)d 15 (53.60) 16 (45.70) 15 (20.27) 0 n/a 
Any Antipsychotic (n)e 11 (39.60) 13 (37.10) 0 0 n/a 
Any Anticonvulsant (n)f 5 (17.90) 21 (60.00) 0 0 n/a 
Hippocampal volume, Left (cm3) 4.41 (0.55) 4.39 (0.49) 4.32 (0.61)  4.33 (0.6) 4.44 (0.60) 
Hippocampal volume, Right (cm3) 4.11 (0.49) 4.07 (0.42) 4.02 (0.55) 3.98 (0.58) 4.41 (0.60) 
All continuous variables are shown as mean (standard deviation); Intelligence Quotient (IQ) was derived from the Wechsler Adult Intelligence Scale-Revised; WMS= Wechsler Memory Scale-III; 
VPA=Verbal Paired Associates; Scaled scores reported for both WMS-VPA measures; BD=Bipolar Disorder;   a Relatives <Patients and Controls; p<0.03; b Patients> Relatives, Controls, all 
p<0.0001; c 59 patients were prescribed more than one psychotropic; d all antidepressants prescribed were serotonin reuptake inhibitors; e all but 3 antipsychotics prescribed were second generation 
agents; f sodium valproate=14; carbamazepine=5; lamotrigine=2; combinations=5  
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Figure 1: Scatterplot showing the distribution of adjusted telomere length in 
the study sample 
 
Compared to unrelated healthy individuals, age-and-sex adjusted telomere length 
was shorter in psychiatrically-well relatives and in relatives with psychiatric 
diagnoses relative to controls (p=0.07; not shown in figure). Lithium-treated patients 
with BD had longer telomere length compared to relatives, regardless of psychiatric 
status, and patients with BD not on lithium.    
 
 
 
Figure 2: Scatterplot of the association between telomere length, hippocampal 
volume and delayed memory in the study sample      
 
 
In the entire sample, telomere length was positively associated with left and right 
hippocampal volume and with delayed recall in the verbal paired associates test.  
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